Paper36070540
A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor-Positive Ovarian Cancer (Study 006).
Tanyi JL and 13 others. J Clin Oncol, 2023. Cited by 151 papers, by iCite.
Cite this record
ConductScience Library. A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor-Positive Ovarian Cancer (Study 006). Papers, record 36070540. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36070540
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor-Positive Ovarian Cancer (Study 006).
- PubMed
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Folate Receptor 1 | Major topic |
| Ovarian Neoplasms | Major topic |
| Humans | |
| Female | |
| Folic Acid | |
| Molecular Imaging |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30 CA022453 | NCI NIH HHS | United States | P30CA022453 | PubMed | NIH RePORTER |
| P30 CA076292 | NCI NIH HHS | United States | P30CA076292 | PubMed | NIH RePORTER |
Trials3
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT03180307 | OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT07469202 | CYTALUX Dose Extension Study | Background | ClinicalTrials.gov | |
| NCT07919509 | A Project Assessing the Safety and Feasibility of Using Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Ovarian Cancer During Surgical Procedures | Background | ClinicalTrials.gov |
Comments and corrections2
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 37082670 | Ovarian cancer-targeted near-infrared fluorophores for fluorescence-guided surgery. | https://conductscience.org/library/papers/37082670 | PubMed |
| Comment in | 37970599 | Pafolacianine, the magic wand of intraoperative imaging of folate-receptor positive ovarian cancer. | https://conductscience.org/library/papers/37970599 | PubMed |
References28
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 9347791 | Most primary cutaneous CD30-positive lymphoproliferative disorders have a CD4-positive cytotoxic T-cell phenotype. | J Invest Dermatol | 1997 | https://conductscience.org/library/papers/9347791 | PubMed |
| 2 | 27306792 | A Novel Tumor-Specific Agent for Intraoperative Near-Infrared Fluorescence Imaging: A Translational Study in Healthy Volunteers and Patients with Ovarian Cancer. | Clin Cancer Res | 2016 | https://conductscience.org/library/papers/27306792 | PubMed |
| 3 | 26110901 | The Value of Intraoperative Near-Infrared Fluorescence Imaging Based on Enhanced Permeability and Retention of Indocyanine Green: Feasibility and False-Positives in Ovarian Cancer. | PLoS One | 2015 | https://conductscience.org/library/papers/26110901 | PubMed |
| 4 | 15853442 | Chemotherapy-induced ovarian failure: manifestations and management. | Drug Saf | 2005 | https://conductscience.org/library/papers/15853442 | PubMed |
| 5 | 31851799 | Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. | N Engl J Med | 2019 | https://conductscience.org/library/papers/31851799 | PubMed |
| 6 | 15745749 | Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. | Anal Biochem | 2005 | https://conductscience.org/library/papers/15745749 | PubMed |
| 7 | 30345884 | Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. | N Engl J Med | 2018 | https://conductscience.org/library/papers/30345884 | PubMed |
| 8 | 21926976 | Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results. | Nat Med | 2011 | https://conductscience.org/library/papers/21926976 | PubMed |
| 9 | 9661918 | Analysis of p53, p21WAF1, and TGF-beta1 in human ductal adenocarcinoma of the pancreas: TGF-beta1 protein expression predicts longer survival. | Am J Clin Pathol | 1998 | https://conductscience.org/library/papers/9661918 | PubMed |
| 10 | 19189636 | Alpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissue. | Anticancer Res | 2008 | https://conductscience.org/library/papers/19189636 | PubMed |
| 11 | 31216226 | Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer. | J Clin Oncol | 2019 | https://conductscience.org/library/papers/31216226 | PubMed |
| 12 | 31362825 | A phase II, multicenter, open-label trial of OTL38 injection for the intra-operative imaging of folate receptor-alpha positive ovarian cancer. | Gynecol Oncol | 2019 | https://conductscience.org/library/papers/31362825 | PubMed |
| 13 | 26491562 | Comparison of Folate Receptor Targeted Optical Contrast Agents for Intraoperative Molecular Imaging. | Int J Mol Imaging | 2015 | https://conductscience.org/library/papers/26491562 | PubMed |
| 14 | 26248049 | Folate Receptor-Beta Has Limited Value for Fluorescent Imaging in Ovarian, Breast and Colorectal Cancer. | PLoS One | 2015 | https://conductscience.org/library/papers/26248049 | PubMed |
| 15 | 18222534 | Folate receptor alpha as a tumor target in epithelial ovarian cancer. | Gynecol Oncol | 2008 | https://conductscience.org/library/papers/18222534 | PubMed |
| 16 | 30254940 | Laparoscopy and Computed Tomography Imaging in Advanced Ovarian Tumors: A Roadmap for Prediction of Optimal Cytoreductive Surgery. | Gynecol Minim Invasive Ther | 2018 | https://conductscience.org/library/papers/30254940 | PubMed |
| 17 | 31970129 | Factors associated with surgical morbidity of primary debulking in epithelial ovarian cancer. | Obstet Gynecol Sci | 2020 | https://conductscience.org/library/papers/31970129 | PubMed |
| 18 | 34304313 | Time to Evolve Terminology from "Debulking" to Cytoreductive Surgery (CRS) in Ovarian Cancer. | Ann Surg Oncol | 2021 | https://conductscience.org/library/papers/34304313 | PubMed |
| 19 | 1234624 | Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. | Natl Cancer Inst Monogr | 1975 | https://conductscience.org/library/papers/1234624 | PubMed |
| 20 | 19189349 | Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). | Cancer | 2009 | https://conductscience.org/library/papers/19189349 | PubMed |
Cited by108
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 151 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42939681 | Validation of a Highly Specific Anti-Human Folate Receptor Alpha Single-Domain Antibody for Rapid Fluorescence-Guided Surgery of Ovarian and Lung Cancer. | Biomolecules | 2026 | https://conductscience.org/library/papers/42939681 | PubMed |
| 42922515 | Development and Optimization of 111In-Dinutuximab-IRDye800, a Dual-Modality Intraoperative Molecular Imaging Agent for Pediatric Neuroblastoma Resection. | bioRxiv | 2026 | https://conductscience.org/library/papers/42922515 | PubMed |
| 42883231 | Near-Infrared Fluorescence Probes for Fluorescence-Guided Surgery: Current Clinical Probes and Emerging Candidates. | Molecules | 2026 | https://conductscience.org/library/papers/42883231 | PubMed |
| 42881460 | Near-infrared fluorescence imaging for ureteral and sentinel lymph node mapping in gynecological minimally invasive surgery: a review of fluorophores and domestic laparoscopic systems. | World J Surg Oncol | 2026 | https://conductscience.org/library/papers/42881460 | PubMed |
| 42860479 | Beyond feasibility: an oncology-first framework for defining the role of robot-assisted surgery in ovarian cancer-patient selection, surgical adequacy, and conversion pathways. | J Robot Surg | 2026 | https://conductscience.org/library/papers/42860479 | PubMed |
| 42847075 | A Molecular Shielding Strategy to Develop Low Protein Binding, Renal Clearable Pan-Cancer Near-Infrared Probes. | Adv Funct Mater | 2026 | https://conductscience.org/library/papers/42847075 | PubMed |
| 42835385 | Delineating precise surgical resection areas: recent advances in NIR-II fluorescence imaging molecular probes. | Front Oncol | 2026 | https://conductscience.org/library/papers/42835385 | PubMed |
| 42826211 | A folate receptor-targeted NIR-II probe improves intraoperative imaging and surgery of metastatic ovarian cancer. | Sci Adv | 2026 | https://conductscience.org/library/papers/42826211 | PubMed |
| 42694955 | Targeting Folate Receptors for the Detection and Selective Treatment of Cancer: Advanced Precision Oncology in Practice. | Int J Biol Sci | 2026 | https://conductscience.org/library/papers/42694955 | PubMed |
| 42657301 | Progress in the Design and Clinical Application of Probes for Fluorescence-Guided Laparoscopic Surgery. | Chem Biomed Imaging | 2026 | https://conductscience.org/library/papers/42657301 | PubMed |
| 42559295 | Clinically accessible drug-based nano-assemblies with self-targeting ability for NIR-II fluorescence imaging-guided surgery in triple-negative breast cancer. | Theranostics | 2026 | https://conductscience.org/library/papers/42559295 | PubMed |
| 42373751 | Imaging the hallmarks of cancer. | Nat Rev Cancer | 2026 | https://conductscience.org/library/papers/42373751 | PubMed |
| 42355661 | Precision at the Margin: Innovations and Challenges in Intraoperative Molecular Imaging for Thoracic Surgery. | J Clin Med | 2026 | https://conductscience.org/library/papers/42355661 | PubMed |
| 42342710 | Multimodal imaging and artificial intelligence for response assessment to neoadjuvant therapy in breast cancer: a comprehensive review. | NPJ Breast Cancer | 2026 | https://conductscience.org/library/papers/42342710 | PubMed |
| 42281988 | Whole-body tomographic fluorescence lifetime imaging of PD-L1 expression. | Res Sq | 2026 | https://conductscience.org/library/papers/42281988 | PubMed |
| 42198268 | Emerging Near-Infrared Targeted Imaging Pharmaceutics for Ovarian Cancer. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/42198268 | PubMed |
| 42165837 | Advancements in Intraoperative Imaging for Enhanced Surgical Precision. | Recent Results Cancer Res | 2026 | https://conductscience.org/library/papers/42165837 | PubMed |
| 42081142 | Translational development of an SGLT2-targeted near-infrared contrast agent for intraoperative imaging of early-stage lung cancer. | EJNMMI Res | 2026 | https://conductscience.org/library/papers/42081142 | PubMed |
| 42052241 | In vivo Fluorescent Molecular Imaging Using Nanobodies Labeled with Next-Generation FNIR-Tag-Dyes. | Res Sq | 2026 | https://conductscience.org/library/papers/42052241 | PubMed |
| 42048455 | An Octopus probe for high-performance >1,300 nm NIR-II fluorescence molecular imaging of cancer. | Proc Natl Acad Sci U S A | 2026 | https://conductscience.org/library/papers/42048455 | PubMed |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| PAFOLACIANINE | CHEMBL4297412 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL4297412 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36070540
GET https://conductscience.org/api/papers/v1/36070540/references?page=2